Edick Paul R insider trades
Edick Paul R has filed 11 Form 4s with the SEC that we hold, for Xeris Biopharma Holdings, Inc. (XERS) (See Remarks, Director), Vistagen Therapeutics, Inc. (VTGN) (Director) and XERS (Chief Executive Officer, Director). Across all of them we count 5 purchases worth $654.4K and 0 sales worth $0 reported on Form 4. None of these purchases or sales is dated in the last 12 months. The largest single trade was a purchase of 200,000 shares of Xeris Biopharma Holdings, Inc. worth $416.0K, dated 2021-11-11. The first filing on our record is dated 2021-10-05 and the latest 2025-11-04.
Xeris Biopharma Holdings, Inc. (XERS)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-11-11 | P, purchase reported on Form 4 | 200,000 | $416.0K | 2021-11-12 |
| 2021-11-15 | P, purchase reported on Form 4 | 20,000 | $45.6K | 2021-11-16 |
| 2022-05-12 | P, purchase reported on Form 4 | 100,000 | $140.0K | 2022-05-13 |
| 2022-12-13 | P, purchase reported on Form 4 | 20,000 | $29.0K | 2022-12-14 |
| 2023-08-09 | P, purchase reported on Form 4 | 10,000 | $23.8K | 2023-08-09 |
Vistagen Therapeutics, Inc. (VTGN)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
XERS (XERS)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Counted from the Form 4 filings this reporting owner (SEC CIK 1531178) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms